loading…
loading…
loading…
TEAMKY Demonstration
Approval Period: January 1, 2025 through December 31, 2029
Page 108 of 155 Demonstration Goal: Increased number of SUD providers offering residential treatment, especially IMDs. Evaluation Hypothesis: The demonstration will increase the number of SUD providers offering residential treatment, especially IMDs.
Primary Driver (Increase the number of Medicaid SUD providers, overall and specifically delivering MAT)
Providers offering residential treatment for SUD N/A Number of providers billing for residential treatment for SUD Total number of beneficiaries
Claims data
Provider enrollment data Descriptive statistics
Interrupted time series without comparison group IMD facilities offering treatment for SUD N/A Number of IMD facilities billing for treatment for SUD Total number of beneficiaries Providers offering residential treatment for SUD in areas with greatest need N/A Number of providers billing for residential treatment for SUD, by county Total number of beneficiaries, by county
Claims data
Provider enrollment data
Descriptive statistics
IMD facilities offering treatment for SUD in areas with greatest need N/A Number of IMD facilities billing for treatment for SUD, by county Total number of beneficiaries, by county Demonstration Goal: Increased utilization of SUD treatment services. Evaluation Hypothesis: The demonstration will increase the utilization of SUD treatment services.
Primary Driver (Increase the utilization of SUD treatment services, overall and specifically MAT including methadone) Percentage of beneficiaries with newly initiated SUD treatment/diagnosis N/A Number of beneficiaries with SUD diagnosis and SUD- related service but not in 3 months preceding measurement period Total number of beneficiaries
Claims data
Descriptive statistics
Interrupted time series without comparison group Percentage of beneficiaries with SUD diagnosis who used outpatient services for SUD N/A Number of beneficiaries with SUD diagnosis who used outpatient services for SUD Total number of beneficiaries Percentage of beneficiaries with SUD diagnosis who used residential treatment services for SUD N/A Number of beneficiaries with SUD diagnosis who used residential treatment services for SUD Total number of beneficiaries Percentage of beneficiaries with SUD (OUD) diagnosis who used MAT N/A Number of beneficiaries with SUD diagnosis who used MAT Total number of beneficiaries Percentage of beneficiaries with SUD (OUD) diagnosis who received methadone as part of MAT N/A Number of beneficiaries with SUD diagnosis who received methadone as part of MAT Total number of beneficiaries Continuity of pharmacotherapy for OUD* NQF #3175 Number of beneficiaries who have at least 180 days of continuous pharmacotherapy Number of beneficiaries with a diagnosis of OUD